Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat vs standard of care in Fabry disease with left ventricular hypertrophy
2023-509715-91-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial in Fabry disease (FD) comparing Venglustat with Usual standard of care (2 arms). Primary endpoint: Slope of left ventricular mass index by cardiac MRI. Planned start Jun 2024; status: authorised.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2023-509715-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509715-91-00.